drugset
drugset / Trial / NCT02722369

STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)

NCT02722369 ↗

Phase 2 Terminated 72 enrolled University College, London
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether the combination of gemcitabine/carboplatin with hydroxychloroquine (HCQ) is associated with an improved clinical outcome (progression free and overall survival) compared with chemotherapy alone in patients with small cell lung cancer (SCLC)

Timeline

Start
2017-03-14
Primary completion
2021-03-12
Completion
2021-03-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoposide Small molecule 100 mg Intravenous
Subject Gemcitabine Small molecule 1200 mg/m2 Intravenous
Subject Hydroxychloroquine Small molecule 400 mg Oral
Background Carboplatin Small molecule 5 unknown Intravenous

Indications

small cell lung carcinoma